Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

Inclusion Criteria: * Postmenopausal women, defined as: * 12 months of spontaneous amenorrhea; * OR 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels \>40 mIU/mL; * OR 6 weeks post surgical bilateral oophorectomy with or without hysterectomy. * Be ≥ 40 and ≤ 65 years of age; * Have a body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2; * Minimum of 7 moderate to severe hot flushes per day or 50 per week, as quantified from daily diary recordings during at least 7 days preceding randomization to trial medication; * Able to handle the electronic diary device after training and having at least 80% compliance on complete daily diary entries during the period prior to randomization; * Give voluntary written Informed Consent (IC) after the scope and nature of the investigation had been explained, before screening evaluations. Exclusion Criteria: * History or presence of any malignancy, except non-melanoma skin cancers; * Any clinically unstable or uncontrolled renal, hepatic, endocrine, respiratory, hematological, neurological, cardiovascular or cerebrovascular disease that would put the subject at safety risk or mask measure of efficacy; * History of seizures or epilepsy; * History or presence of clinically significant depression or other psychiatric disorder which, in the opinion of the investigator, might compromise or confound the subject's participation in the trial; * Abnormal clinically relevant vaginal bleeding; * Any clinically relev…